A Phase 1b study of its REP-0003 mRNA therapy in patients with homozygous familial hypercholesterolemia
Latest Information Update: 30 Jan 2025
Price :
$35 *
At a glance
- Drugs REP-003 (Primary)
- Indications Hyperlipoproteinaemia type II
- Focus Adverse reactions
- 30 Jan 2025 New trial record